Drug Name:
AFEDITAB CR Rx
Generic Name and Formulations:
Nifedipine 30mg, 60mg; ext-rel tabs.
Company:
Actavis
Therapeutic Use:
Indications for AFEDITAB CR:
Hypertension.
Adult:
Swallow whole. Initially 30mg once daily, titrate over 7–14 days; usual maintenance dose: 30–60mg once daily; max 90mg/day.
Children:
Not recommended.
Warnings/Precautions:
Aortic stenosis. Angina. Severe obstructive coronary artery disease. Heart failure. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers: not recommended.
Pharmacological Class:
Calcium channel blocker (CCB) (dihydropyridine).
Interactions:
Hypotension, angina and heart failure possible with β-blockers (esp. timolol). Potentiated by quinidine (monitor heart rate; adjust dose); diltiazem, verapamil, doxazosin, ketoconazole, itraconazole, fluconazole, cimetidine, quinupristin/dalfopristin, erythromycin, nefazodone, valproic acid, (reduce nifedipine dose); amprenavir, atazanavir, delavirine, fosamprenavir, indinavir, nelfinavir, ritonavir, grapefruit juice (avoid). Antagonized by rifampin, rifapentine, phenytoin, phenobarbitone, carbamazepine, St. John's Wort. Potentiates digoxin, tacrolimus (monitor). Antagonizes doxazosin. Hypotension possible with fentanyl. Monitor oral anticoagulants. Hyperglycemia with acarbose.
Adverse Reactions:
Headache, flushing/heat sensation, fatigue, dizziness, constipation, nausea, edema; rare: increased angina, acute MI.
How Supplied:
Tabs—100, 500
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |